Who are Zegalogue's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): morphine and glucagon, Glucagon 12.5ng/kg/min, Low-Dose Glucagon, Glucagon Hydrochloride Solution, GlucaGen® HypoKit®, Glucagon Nasal Powder.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dasiglucagon.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Zegalogue — Competitive Intelligence Brief

Zegalogue (DASIGLUCAGON) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antihypoglycemic Agent [EPC]. Area: Metabolic.

marketed Antihypoglycemic Agent [EPC] Glucagon receptor Metabolic Live · refreshed every 30 min

Target snapshot

Zegalogue (DASIGLUCAGON) — Zealand Pharma. Zegalogue works by stimulating the release of glucose from stored energy sources in the body.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Zegalogue TARGET	DASIGLUCAGON	Zealand Pharma	marketed	Antihypoglycemic Agent [EPC]	Glucagon receptor	2021-01-01
morphine and glucagon	morphine and glucagon	National Taiwan University Hospital	marketed	Opioid analgesic + glucagon (hormone)	Mu-opioid receptor (morphine); glucagon receptor (glucagon)
Glucagon 12.5ng/kg/min	Glucagon 12.5ng/kg/min	Cambridge University Hospitals NHS Foundation Trust	marketed	Glucagon receptor agonist	Glucagon receptor (GCGR)
Low-Dose Glucagon	Low-Dose Glucagon	Steno Diabetes Center Copenhagen	marketed	Glucagon receptor agonist	Glucagon receptor (GCGR)
Glucagon Hydrochloride Solution	Glucagon Hydrochloride Solution	Eli Lilly and Company	phase 3	Glucagon receptor agonist	Glucagon receptor (GCGR)
GlucaGen® HypoKit®	GlucaGen® HypoKit®	Adocia	phase 3	Glucagon receptor agonist	Glucagon receptor (GCGR)
Glucagon Nasal Powder	Glucagon Nasal Powder	Eli Lilly and Company	phase 3	Glucagon receptor agonist	Glucagon receptor (GCGR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antihypoglycemic Agent [EPC] class)

Zealand Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zegalogue — Competitive Intelligence Brief. https://druglandscape.com/ci/dasiglucagon. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab